Opinion|Videos|March 31, 2025
JADE COMPARE: Considerations for Comparisons Among Systemic Agents in Atopic Dermatitis
Panelists discuss how the JADE COMPARE study (Bieber 2021) found similar EASI-75 response rates at 16 weeks for abrocitinib (71.0% at 200 mg, 60.3% at 100 mg) and dupilumab (65.5%). Abrocitinib had more nausea/acne; dupilumab had more conjunctivitis. Adverse effect (AE) withdrawal rates were low.
Advertisement
Episodes in this series
Video content above in prompted by the following:
- Discuss the JADE COMPARE study, where abrocitinib was compared to a placebo and dupilumab (Bieber 2021). When would you recommend a Janus kinase inhibitor over a biologic?
- 71.0% of the 221 patients taking 200 mg abrocitinib and 60.3% of the 229 patients taking 100 mg abrocitinib achieved EASI-75 response at week 16.
- 65.5% of the 232 patients taking dupilumab achieved EASI-75 response at week 16.
- There was no significant difference in EASI-75 response between patients taking abrocitinib (with either dose) and those taking dupilumab.
- Nausea and acne were more common in the abrocitinib patients than in the dupilumab patients; conjunctivitis was more common in the dupilumab patients.
- 4.4% of patients taking 200 mg abrocitinib, 2.5% of patients taking 100 mg abrocitinib, and 3.3% of patients taking dupilumab withdrew due to an AE.
Advertisement
Related to this article
KT-621, an oral STAT6 degrader, cut mean EASI by 62.6% after 4 weeks with no treatment-related adverse events in a phase 1b atopic dermatitis study.
Phase 2 and 3 data show difamilast 1% ointment improved severity and itch within 1 week in adults and children with mild to moderate atopic dermatitis.
In the phase 2b EVIDENCES X trial, saroglitazar 4 mg resolved MASH without worsening fibrosis in 39.1% of patients vs 13.7% with placebo at 52 weeks.
Dave Singh, MD, reflects on 2027 GOLD report refinements, from mucus plugs and early COPD to biologics awaiting regulatory approval.
Retrospective data show semaglutide 2.4 mg was linked to lower liver enzymes, weight, and HbA1c in MASH, including vs resmetirom in a real-world cohort.
Francesca Polverino, MD, PhD, explains how oxidized and reduced IL-33 drive mucus dysfunction and inflammation in COPD, and why mucus plugs matter.
Phase 2 ENHANCE and ENRICH data show BRII-179 plus elebsiran and peginterferon increased HBsAg loss in chronic HBV, with priming halving peginterferon use.
Pooled phase 2 data show fazirsiran 200 mg cut intrahepatic Z-AAT by about 90% vs placebo in AATD liver disease, with stable lung function through the OLE.
Advertisement
Advertisement
Trending on HCPLive
1
2027 GOLD Report Update Preview: Changes in COPD Treatment, Biologics
2
Noninvasive Models Underestimate CSPH in MASH Cirrhosis vs HVPG
3
IDEAL: Seladelpar Achieves ALP Normalization in Second-Line PBC
4
Real-World Resmetirom Data Show Liver Stiffness Gains in MASH
5